Clinical Trial Update: Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses. [Phase 1]

View source ↗

Summary

Phase 1 safety study assessing cG250 antibody labeled with 124-Iodine for diagnosing renal masses has been completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Kidney Cancer
• Renal Cell Carcinoma

Drugs mentioned

• 124-Iodine (Iodine-124)
• cG250

Snippet

Sponsor: Ludwig Institute for Cancer Research | Conditions: Cancer of Kidney, Kidney Cancer | Phase 1 | Status: COMPLETED | Results posted: 2021-05-14